Intranasal mouse model

In a mouse model of aerosol sensitization to birch pollen we previously demonstrated that intranasal as well as oral administration of the major birch pollen allergen Bet v 1 prevented allergic sensitization, airway inflammation and airway hyperresponsiveness [28], Similar effects were achieved using hypoallergenic derivates of Bet v 1, containing the immunodominant T cell peptides but not the anaphylactogenic B cell epitopes, for intranasal tolerance induction [60],... 

In the mouse model described here, pneumonia is induced after the intranasal instillation of S. pneumoniae. When using this model for evaluation of antimicrobial agents, therapeutic treatment should start after the infection has already been established in the lungs (6-12 h after bacterial inoculation). 

Good evidence from animal models indicates that a4 1 (VLA ) is a viable drug target for asthma. Monoclonal antibodies (mAb) against the a4 subunit of VLA-4 have proven efficacious in asthma models in five different species. For example, in a mouse model of asthma, intravenously administered anti-a4 mAb eliminated eosinophilia but did not affect AHR. In contrast, when delivered intranasally, the mAb blocked both airway inflammation and AHR (54). The small-molecule VLA-4 antagonist (2S)-3-(4-Dimethylcarbamoyloxyphenyl)-2- ((4R)-5, 5-dimethyl-3-(l-methyl-lH-pyrazole-4sulfonyl)thiazolidine -... 

Maurice T, Mustafa MH, Desrumaux C, Keller E, Naert G, Garcia-Barcelo ML et al (2013) Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the A(i25-35 non-transgenic mouse model of Alzheimer s disease. J Psychopharmacol 27(11) 1044-1057... 

IL-4 Modulators/Clinical Data. Different approaches have been taken to neutralize IL-4 activity, including soluble IL-4 receptor, antibodies against IL-4, and mutated IL-4, which acts as an antagonist of the receptor. In a mouse model of airway inflammation, soluble IL-4 receptor administered intranasally, before allergen challenge, results in a reduction of eosinophil infiltration, V-CAM expression, and mucus hypersecretion (417). This treatment, however, did not change airway hyperreactivity in response to methacholine. 

Amidi, M., Romeijn, S. G., Coos Verhoef, f., Junginger, H. E., Bungener, L., Huckriede, A., Crommelin, D. J. A., and Jiskoot, W. (2007). N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination Biological properties and immunogenicity in a mouse model. Vaccine, 25,144-153. 

Intranasal administration of purified 35-kDa protein significantly reduced inflammation of the airway and lung parenchyma and improved the physiological function of the lungs during airway hyperreactivity in a mouse model of allergen-induced asthma without compromising systemic immunity or chemoattraction at extrapul-monary sites [24]. 

Moreover, intranasally delivered theophylline incorporated into thiolated chit-osan nanoparticles as carrier matrix was developed and investigated for its capacity to relieve allergic asthma. In a mouse model of allergic asthma, the combination of theophylline with thiolated chitosan nanoparticles accelerated the efficacy of the drug in comparison to theophylline alone [70]. 

---